Document is current
Any future updates will be listed below
-
Authors
Subudhi, Sumit K
Siddiqui, Bilal A https://orcid.org/0000-0002-6806-1294
Zarrabi, Kevin K
Kelly, William K
Drake, Charles G
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct05125016 at ClinicalTrials.govnct05519449 at ClinicalTrials.govDocuments that mention this clinical trial
Phase 1/2 study of REGN4336 alone or in combination with cemiplimab or nezastomig in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).
https://doi.org/10.1200/jco.2025.43.5_suppl.tps295
The path forward for T cell engagers in patients with prostate cancer
https://doi.org/10.1136/jitc-2025-013905
nct05997615 at ClinicalTrials.govDocuments that mention this clinical trial
Impact of tumor localization on antitumor immunity with conditionally activated CTLA-4 blockade
https://doi.org/10.1136/jitc-2024-010566
The path forward for T cell engagers in patients with prostate cancer
https://doi.org/10.1136/jitc-2025-013905
nct06691984 at ClinicalTrials.govDocuments that mention this clinical trial
The path forward for T cell engagers in patients with prostate cancer
https://doi.org/10.1136/jitc-2025-013905
nct06613100 at ClinicalTrials.govDocuments that mention this clinical trial
The path forward for T cell engagers in patients with prostate cancer
https://doi.org/10.1136/jitc-2025-013905
nct06555796 at ClinicalTrials.govDocuments that mention this clinical trial
The path forward for T cell engagers in patients with prostate cancer
https://doi.org/10.1136/jitc-2025-013905
A phase 1b, open-label, multicenter study of xaluritamig in patients with newly diagnosed localized intermediate- or high-risk prostate cancer in the neoadjuvant setting.
https://doi.org/10.1200/jco.2025.43.5_suppl.tps434
nct04898634 at ClinicalTrials.govDocuments that mention this clinical trial
A phase 1b, open-label, multicenter study of xaluritamig in patients with biochemical recurrence of prostate cancer after definitive therapy.
https://doi.org/10.1200/jco.2025.43.5_suppl.tps435
The path forward for T cell engagers in patients with prostate cancer
https://doi.org/10.1136/jitc-2025-013905
nct07164443 at ClinicalTrials.govDocuments that mention this clinical trial
The path forward for T cell engagers in patients with prostate cancer
https://doi.org/10.1136/jitc-2025-013905
Pasritamig, a First-in-Class, Bispecific T-Cell Engager Targeting Human Kallikrein 2, in Metastatic Castration-Resistant Prostate Cancer: A Phase I Study
https://doi.org/10.1200/jco-25-00678
nct07225946 at ClinicalTrials.govDocuments that mention this clinical trial
The path forward for T cell engagers in patients with prostate cancer
https://doi.org/10.1136/jitc-2025-013905
nct04702737 at ClinicalTrials.govDocuments that mention this clinical trial
The path forward for T cell engagers in patients with prostate cancer
https://doi.org/10.1136/jitc-2025-013905
nct03972657 at ClinicalTrials.govDocuments that mention this clinical trial
Phase 1b study of tarlatamab in de novo or treatment-emergent neuroendocrine prostate cancer (NEPC).
https://doi.org/10.1200/jco.2024.42.16_suppl.5012
The path forward for T cell engagers in patients with prostate cancer
https://doi.org/10.1136/jitc-2025-013905
nct06085664 at ClinicalTrials.govDocuments that mention this clinical trial
A phase 1/2 study of nezastomig (anti-PSMA×CD28) with or without cemiplimab (anti–PD-1) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and clear cell renal cell carcinoma (ccRCC).
https://doi.org/10.1200/jco.2025.43.5_suppl.tps293
275 All-in-one CAR T cell platform for safe and effective targeting of metastatic castration-resistant prostate cancer
https://doi.org/10.1136/jitc-2025-sitc2025.0275
646 A pilot presurgical trial of REGN5678 (Anti-PSMAxCD28) in patients with high-risk, localized prostate cancer followed by radical prostatectomy
https://doi.org/10.1136/jitc-2024-sitc2024.0646
Preliminary results from a phase 1/2 study of co-stimulatory bispecific PSMAxCD28 antibody REGN5678 in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).
https://doi.org/10.1200/jco.2023.41.6_suppl.154
The path forward for T cell engagers in patients with prostate cancer
https://doi.org/10.1136/jitc-2025-013905
nct06826768 at ClinicalTrials.govDocuments that mention this clinical trial
646 A pilot presurgical trial of REGN5678 (Anti-PSMAxCD28) in patients with high-risk, localized prostate cancer followed by radical prostatectomy
https://doi.org/10.1136/jitc-2024-sitc2024.0646
The path forward for T cell engagers in patients with prostate cancer
https://doi.org/10.1136/jitc-2025-013905
nct06095089 at ClinicalTrials.govDocuments that mention this clinical trial
The path forward for T cell engagers in patients with prostate cancer
https://doi.org/10.1136/jitc-2025-013905
nct05585034 at ClinicalTrials.govDocuments that mention this clinical trial
The path forward for T cell engagers in patients with prostate cancer
https://doi.org/10.1136/jitc-2025-013905
nct05369000 at ClinicalTrials.govDocuments that mention this clinical trial
The path forward for T cell engagers in patients with prostate cancer
https://doi.org/10.1136/jitc-2025-013905
nct06691984 at ClinicalTrials.govDocuments that mention this clinical trial
Phase I/II trial of LAVA-1207, a novel bispecific gamma-delta T-cell engager alone, or with low dose IL-2 or pembrolizumab, in metastatic castration resistant prostate cancer (mCRPC).
https://doi.org/10.1200/jco.2024.42.16_suppl.tps2672
Therapeutic avenues for γδ T cells in cancer
https://doi.org/10.1136/jitc-2023-007955
Early dose escalation of LAVA-1207, a novel bispecific gamma-delta T-cell engager (Gammabody), in patients with metastatic castration-resistant prostate cancer (mCRPC).
https://doi.org/10.1200/jco.2023.41.6_suppl.153
The path forward for T cell engagers in patients with prostate cancer
https://doi.org/10.1136/jitc-2025-013905
nct06693687 at ClinicalTrials.govDocuments that mention this clinical trial
The path forward for T cell engagers in patients with prostate cancer
https://doi.org/10.1136/jitc-2025-013905
nct04571398 at ClinicalTrials.govDocuments that mention this clinical trial
The path forward for T cell engagers in patients with prostate cancer
https://doi.org/10.1136/jitc-2025-013905
nct05812274 at ClinicalTrials.govDocuments that mention this clinical trial
The path forward for T cell engagers in patients with prostate cancer
https://doi.org/10.1136/jitc-2025-013905
nct06826768 at ClinicalTrials.govDocuments that mention this clinical trial
The path forward for T cell engagers in patients with prostate cancer
https://doi.org/10.1136/jitc-2025-013905
A phase IV study of ApricityCARE program for cancer adverse events rapid evaluation to improve treatment outcomes of ethnic/racial minority patients with non-small cell lung cancer (NSCLC) receiving immune checkpoint inhibitors (ICI).
https://doi.org/10.1200/jco.2024.42.16_suppl.tps1642
nct05125016 at ClinicalTrials.govDocuments that mention this clinical trial
The path forward for T cell engagers in patients with prostate cancer
https://doi.org/10.1136/jitc-2025-013905
nct06095089 at ClinicalTrials.govDocuments that mention this clinical trial
Phase 1/2 study of REGN4336 alone or in combination with cemiplimab or nezastomig in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).
https://doi.org/10.1200/jco.2025.43.5_suppl.tps295
The path forward for T cell engagers in patients with prostate cancer
https://doi.org/10.1136/jitc-2025-013905
Documents that mention this clinical trial
The path forward for T cell engagers in patients with prostate cancer
https://doi.org/10.1136/jitc-2025-013905
- License Information
